"Until now, nail changes associated with GLP-1 therapies had essentially been anecdotal," said study author Dr. Charles Taïeb. "Our findings show a clear association, but they also underline an important point: not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself."

The caution is warranted. Around half of the users reported nail problems before starting treatment. When researchers adjusted for pre-existing dermatological conditions and nutritional deficiencies, the strength of some associations weakened — although nail detachment and discoloration remained roughly two to three times more frequent among GLP-1 users even after adjustment.

Hair loss and scalp inflammation

A companion study, involving the same participants, found that hair and scalp changes were also significantly more common among GLP-1 users. Unusual hair loss affected 50% of users versus 34% of controls. Loss of hair volume or density affected 42% versus 19%. Hair loss that began after treatment started was more than twice as common among users (26% versus 12%), and scalp redness appeared roughly three times as often.

One pattern stood out: hair loss rarely occurred alone. Most cases came with scalp symptoms such as itching, redness or scaling.

"This suggests that what is happening on the scalp may go beyond the classical shedding seen after rapid weight loss and involve an inflammatory component," explained study author Dr. Bruno Halioua. "Scalp inflammation was the rule rather than the exception, which clinicians do not currently look for and which may be treatable."

What patients should take away

Halioua stressed awareness over alarm. "These changes are frequent, usually benign, and are not a reason to stop an effective treatment on one's own initiative," he said. "Anyone who notices hair shedding, an itchy or red scalp or nail changes should mention it to their doctor rather than discontinue therapy."

Both studies carry important limitations. They were cross-sectional — a snapshot at one point in time rather than a follow-up over months or years — and they relied on patient-reported symptoms rather than clinical examination. That design can identify associations but cannot prove that GLP-1 treatment caused the changes.

The research team now plans prospective studies that will follow patients from the start of treatment, using standardized dermatological examinations and biological monitoring. The goal is to establish when these changes develop, why they occur and whether they are reversible.

Until those results arrive, the findings offer a clear but preliminary signal: doctors and patients on GLP-1 therapies should pay attention to nails and scalp — and treat both as a conversation to have with a physician, not a reason to quit.